To further verify that NTP therapy for lung cancer is via the RBMS1/YTHDF1/S100P signaling axis, we re‐expressed RBMS1 in A549 cells with NTP treatment and found that restoration of RBMS1 almost fully reversed the NTP‐induced inhibition of cell migration and invasion, as judged by transwell migration and invasion assays (Figure 6E and Figure S5A, Supporting Information). The gene discussed is RBMS1; the disease is lung carcinoma.